Literature DB >> 1649487

[Central and peripheral neurologic lesions in primary Gougerot-Sjögren syndrome. Clinicopathological study of a case].

S Bakchine1, C Duyckaerts, L Hassine, M P Chaunu, E Turell, B Wechsler, F Chain.   

Abstract

A 51 year old woman presented with cerebellar ataxia and paralysis of conjugate lateral movement of the eyes. She had xerophtalmia and xerostomia. Biopsy of minor salivary glands showed mononuclear infiltrates typical of Sjögren's syndrome. Peripheral neuropathy was of the axonal type, and nerve biopsy showed a vasculitis made of a mononuclear infiltrate with only a few polymorphonuclears. The patient deteriorated despite corticosteroid therapy, plasma exchange and cyclophosphamide. Ciclosporin seemed to be transitorily beneficial. Epileptic seizures (auditory hallucinations) occurred. MRI showed hypersignal in the right temporal lobe. At post-mortem examination, a small ischaemic lesion with a large lymphocytic infiltrate was present in the left putamen. Neuronal loss and gliosis with some rod cells and glial stars were found in the brainstem, dentate nucleus and internal part of the right temporal lobe. Inflammatory changes were limited. The posterior columns of the spinal cord were pale, and some residual nodules of Nageotte were present in the spinal ganglia. These lesions were similar to those seen in encephalomyelitic syndromes associated with carcinoma. Lesions of the peripheral nerves were associated with vasculitis but changes in the central nervous system were morphologically similar to those observed as remote effects of carcinoma.

Entities:  

Mesh:

Year:  1991        PMID: 1649487

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  14 in total

1.  Orofacial dystonia related to Sjogren's syndrome.

Authors:  Sokratis G Papageorgiou; Theodoros Kontaxis; Anastasios Bonakis; Nikolaos Kalfakis
Journal:  Clin Rheumatol       Date:  2007-01-16       Impact factor: 2.980

Review 2.  Sjögren's syndrome accompanied with interstitial cystitis: a case report and review of the literature.

Authors:  Dongfeng Liang; Jinshan Lu; Aitao Guo
Journal:  Clin Rheumatol       Date:  2014-01-07       Impact factor: 2.980

3.  Asymptomatic cerebral involvement in Sjögren's syndrome: MRI findings of 15 cases.

Authors:  L Pierot; C Sauve; J M Leger; N Martin; A C Koeger; B Wechsler; J Chiras
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

4.  Primary Sjögren Syndrome with tumefactive central nervous system involvement.

Authors:  J Sanahuja; S Ordoñez-Palau; R Begué; L Brieva; D Boquet
Journal:  AJNR Am J Neuroradiol       Date:  2008-09-10       Impact factor: 3.825

5.  Transient musical hallucinosis of central origin: a review and clinical study.

Authors:  P Paquier; P van Vugt; P Bal; P Cras; P M Parizel; J van Haesendonck; W Creten; J J Martin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

Review 6.  Myelopathy in Sjögren's syndrome: role of nonsteroidal immunosuppressants.

Authors:  Susan J Rogers; Christopher S Williams; Gustavo C Román
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Asymmetric cerebellar ataxia and limbic encephalitis as a presenting feature of primary Sjögren's syndrome.

Authors:  Kiren Collison; Jeremy Rees
Journal:  J Neurol       Date:  2007-09-12       Impact factor: 6.682

8.  Neurological Disorders in Primary Sjögren's Syndrome.

Authors:  Gabriel J Tobón; Jacques-Olivier Pers; Valérie Devauchelle-Pensec; Pierre Youinou
Journal:  Autoimmune Dis       Date:  2012-03-05

9.  Higher frequency of brain abnormalities in neuromyelitis optica spectrum disorder patients without primary Sjögren's syndrome.

Authors:  Li-Na Gu; Min Zhang; Hui Zhu; Jing-Yao Liu
Journal:  Neural Regen Res       Date:  2016-10       Impact factor: 5.135

10.  Primary Sjogren's Syndrome Associated With Treatment-Resistant Obsessive-Compulsive Disorder.

Authors:  Lawrence T C Ong; Gary Galambos; David A Brown
Journal:  Front Psychiatry       Date:  2017-07-11       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.